Utility of serum CA19-9 in diagnosis of cholangiocarcinoma:In comparison with CEA

被引:23
|
作者
Xing-Lei Qin Zuo-Ren Wang Jing-Sen Shi Lin Wang
机构
关键词
Utility of serum CA19-9 in diagnosis of cholangiocarcinoma; CA;
D O I
暂无
中图分类号
R735.8 [胆囊、胆道肿瘤];
学科分类号
100214 ;
摘要
AIM:The diagnosis of cholangiocarcinoma is often difficult,making management approaches problematic.A reliableserum marker for cholangiocarcinoma would be a usefuldiagnostic test.The aims of our study were to evaluate theusefulness of a serum CA19-9 determination in the diagnosisof cholangiocarcinoma.METHODS:We prospectively measured serum CA19-9 andCEA concentrations in patients with cholangiocarcinoma(n=35),benign biliary diseases (n=92),and healthyindividuals (n=15).Serum CA19-9 and CEA concentrationswere measured by an immunoradiometric assay withoutknowledge of the clinical diagnosis.RESULTS:The sensitivity of a CA19-9 value >37 KU·L-1and a CEA value >22 μg·L-1in diagnosing cholangiocarcinomawere 77.14% and 68.57%,respectively.When comparedwith the benign biliary diseases group,the true negativerates of serum CA19-9 and CEA were 84.78% and 81.52%,respectively.The false positive rates of serum CA19-9 andCEA were 15.22% and 18.48%,whereas the accuracy ofserum CA19-9 and CEA were 82.68% and 77.95%,respectively.Serum CA19-9 and CEA concentrations weresignificantly elevated (P<0.001 and P<0.05) in patients withcholangiocarcinoma (290.31±5.34 KU·L-1and 36.46±18.03μg·L-1) compared with patients with benign biliary diseases(13.38±2.59 KU·L-1and 13.84±3.85 μg·L-1) and healthyindividuals (12.78±3.69 KU·L-1and 11.48±3.37 μg·L-1).In 15patients undergoing curative resection of cholangiocarcinoma,the mean serum CA19-9 concentration was decreased froma preoperative level of 286.41±4.36 KU·L-1to a postoperativelevel of 62.01±17.43 KU·L-1(P<0.001),and the mean serumCEA concentration from 39.41±24.35 μg·L1to 28.69±11.03μg·L-1(P<0.05).In patients with cholangiocarcinoma,however,no correlation was found between serum CEA andCA19-9 concentrations (r=0.036).CONCLUSION:These data suggest that the serum CA19-9determination is a useful addition to the available tests for thedifferential diagnosis of cholangiocarcinoma.Serum CA19-9 isan effective tumor marker in diagnosing cholangiocarcinoma,deciding whether the tumor has been radically resected andmonitoring effect of treatment.
引用
收藏
页码:427 / 432
页数:6
相关论文
共 50 条
  • [1] Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: In comparison with CEA
    Qin, Xing-Lei
    Wang, Zuo-Ren
    Shi, Jing-Sen
    Lu, Min
    Wang, Lin
    He, Quan-Ru
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2004, 10 (03) : 427 - 432
  • [2] Serum CEA, CA125, CA19-9, and CA724 levels for the diagnosis and staging of cholangiocarcinoma.
    Deng, Yawen
    Zhong, Rihui
    Xie, Xiaoying
    Xiong, Xuxia
    He, Jian
    Peng, Linhui
    Zeng, Hua
    Duan, Chaohui
    [J]. BIOMEDICAL RESEARCH-INDIA, 2017, 28 (03): : 1413 - 1418
  • [3] Clinical utility of serum CEA, CA72-4 and CA19-9 in the diagnosis and staging of gastric carcinoma.
    Park, S
    Park, S
    Park, M
    Kim, Y
    Koo, J
    [J]. GASTROENTEROLOGY, 2000, 118 (04) : A266 - A266
  • [4] Serum N-glycans outperform CA19-9 in diagnosis of extrahepatic cholangiocarcinoma
    Wang, Mengmeng
    Fang, Meng
    Zhu, Jianhui
    Feng, Huijuan
    Warner, Elisa
    Yi, Changhong
    Ji, Jun
    Gu, Xing
    Gao, Chunfang
    [J]. ELECTROPHORESIS, 2017, 38 (21) : 2749 - 2756
  • [5] The Impact of Preoperative CA19-9 and CEA on Outcomes of Patients with Intrahepatic Cholangiocarcinoma
    Amika Moro
    Rittal Mehta
    Kota Sahara
    Diamantis I. Tsilimigras
    Anghela Z. Paredes
    Ayesha Farooq
    J. Madison Hyer
    Itaru Endo
    Feng Shen
    Alfredo Guglielmi
    Luca Aldrighetti
    Matthew Weiss
    Todd W. Bauer
    Sorin Alexandrescu
    George A. Poultsides
    Shishir K. Maithel
    Hugo P. Marques
    Guillaume Martel
    Carlo Pulitano
    Olivier Soubrane
    Bas G. Koerkamp
    Kazunari Sasaki
    Timothy M. Pawlik
    [J]. Annals of Surgical Oncology, 2020, 27 : 2888 - 2901
  • [6] Clinical Significance of Preoperative Serum CEA, CA125, and CA19-9 Levels in Predicting the Resectability of Cholangiocarcinoma
    Fang, Tianyi
    Wang, Hao
    Wang, Yufu
    Lin, Xuan
    Cui, Yunfu
    Wang, Zhidong
    [J]. DISEASE MARKERS, 2019, 2019
  • [7] The Impact of Preoperative CA19-9 and CEA on Outcomes of Patients with Intrahepatic Cholangiocarcinoma
    Moro, Amika
    Mehta, Rittal
    Sahara, Kota
    Tsilimigras, Diamantis, I
    Paredes, Anghela Z.
    Farooq, Ayesha
    Hyer, J. Madison
    Endo, Itaru
    Shen, Feng
    Guglielmi, Alfredo
    Aldrighetti, Luca
    Weiss, Matthew
    Bauer, Todd W.
    Alexandrescu, Sorin
    Poultsides, George A.
    Maithel, Shishir K.
    Marques, Hugo P.
    Martel, Guillaume
    Pulitano, Carlo
    Soubrane, Olivier
    Koerkamp, Bas G.
    Sasaki, Kazunari
    Pawlik, Timothy M.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (08) : 2888 - 2901
  • [8] EXPLORE ON DIAGNOSTIC AND PROGNOSTIC VALUES OF EXTRAHEPATIC CHOLANGIOCA RCINOMA: UTILITY OF SERUM CA19-9 AND SERUM CEA
    秦兴雷
    王作仁
    鲁敏
    王林
    何铨儒
    [J]. Journal of Pharmaceutical Analysis, 2004, (02) : 140 - 143
  • [9] The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer
    Ni, XG
    Bai, XF
    Mao, YL
    Shao, YF
    Wu, JX
    Shan, Y
    Wang, CF
    Wang, J
    Tian, YT
    Liu, Q
    Xu, DK
    Zhao, P
    [J]. EJSO, 2005, 31 (02): : 164 - 169
  • [10] CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma
    Loosen, Sven H.
    Roderburg, Christoph
    Kauertz, Katja L.
    Koch, Alexander
    Vucur, Mihael
    Schneider, Anne T.
    Binneboesel, Marcel
    Ulmer, Tom F.
    Lurje, Georg
    Schoening, Wenzel
    Tacke, Frank
    Trautwein, Christian
    Longerich, Thomas
    Dejong, Cornelis H.
    Neumann, Ulf P.
    Luedde, Tom
    [J]. SCIENTIFIC REPORTS, 2017, 7